SL
SUPN icon

Salomon & Ludwin’s Supernus Pharmaceuticals SUPN Stock Holding History

Salomon & Ludwin’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.6K Sell
498
-257
-34% -$12.3K ﹤0.01% 1019
2026
Q1 		$38.1K Buy
755
+257
+52% +$13.1K ﹤0.01% 643
2025
Q4 		$24.6K Buy
498
+95
+24% +$4.62K ﹤0.01% 740
2025
Q3 		$19.5K Buy
+403
New +$16.2K ﹤0.01% 830

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Salomon & Ludwin's SUPN Position: Q2 2026 in Review

Salomon & Ludwin reduced its Supernus Pharmaceuticals (SUPN) stake by 34% in Q2 2026, selling an estimated $12.3K and leaving 498 shares worth $23.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1019.

Salomon & Ludwin first reported a position in SUPN in Q3 2025 and has held it in 4 quarters since. The position peaked at $38.1K in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Salomon & Ludwin held 498 shares of Supernus Pharmaceuticals worth $23.6K as of Q2 2026.
  • Salomon & Ludwin sold 257 Supernus Pharmaceuticals shares in Q2 2026, an estimated $12.3K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #1019 holding.
  • Salomon & Ludwin first reported a position in Supernus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Salomon & Ludwin's Supernus Pharmaceuticals position peaked at $38.1K in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.